Treatment depends on the underlying cause. Non-immune causes are usually treated by treating the underlying cause e.g. sepsis. If there is no obvious non-immune cause, a first step can be to use<unk>  components that are likely to produce the greatest<unk>  increment (less than 3 days old and ABO-matched), while further investigations are performed (testing for HLA antibodies). If an immune cause is suspected and HLA antibodies are detected, then HLA-selected<unk>  components can be used. Although HLA-selected<unk> s lead to improved<unk>  increments at 1 hour post-transfusion, there is currently insufficient evidence to demonstrate their clinical effectiveness at preventing bleeding. If HLA antibodies are not detected, and HPA antibodies are detected, then HPA-selected or crossmatched<unk>  components can be used. HLA and HPA-selected components should not be used if no HLA or HPA antibodies are detected.
Platelet transfusion refractoriness
Pseudothrombocytopenia
COAT platelet defect
Platelet storage pool deficiency
Mechanical hemolytic anemia
Reticulocytopenia
Febrile non-hemolytic transfusion reaction
Transfusion-dependent anemia